You are here

Eli Lilly

Eli Lilly to voluntarily delist from Euronext Paris exchange

Eli Lilly to voluntarily delist from Euronext Paris exchange

Marketwatch

Flag link:

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Fierce Pharma

Flag link:

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Flag link:

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Fierce Pharma

Flag link:

Sigilon Therapeutics approaches the clinic

Sigilon Therapeutics approaches the clinic

EP Vantage

Flag link:

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

Investors Business Daily

oral semaglutide

Flag link:

Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed

Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed

Drug Channels

Flag link:

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

Fierce Pharma

Boehringer Ingelheim

Flag link:

Factbox: Britain's insulin providers prepare for Brexit fallout

Factbox: Britain's insulin providers prepare for Brexit fallout

Yahoo/Reuters

Flag link:

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

RAPS.org

Flag link:

ICER dings Novo's new oral diabetes drug

ICER dings Novo's new oral diabetes drug

Biopharma Dive

oral semaglutide

Boehringer Ingelheim

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Fierce Biotech

non-small cell lung cancer

Flag link:

4 Biotech Stocks With Big Catalysts in September

4 Biotech Stocks With Big Catalysts in September

Motley Fool

Mirati Therapeutics

Pralsetinibdicines

Flag link:

Amgen's Aimovig, under fire from Lilly, loses grip on CGRP share

Amgen's Aimovig, under fire from Lilly, loses grip on CGRP share

Fierce Pharma

Flag link:

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022

BioSpace

Flag link:

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta

Pharmaforum

non-squamous non-small cell lung cancer

Flag link:

Three strategies for managing loss of exclusivity successfully

Three strategies for managing loss of exclusivity successfully

Pharmaforum

market exclusivity

Flag link:

Analysis Shows Eli Lilly’s Half-Price Humalog Generic Is Not Readily Available Across the U.S.

Analysis Shows Eli Lilly’s Half-Price Humalog Generic Is Not Readily Available Across the U.S.

BioSpace

Flag link:

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

Endpoints

monoclonal antibodies

ankylosing spondylitis

Flag link:

Pages